NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
PTN
Palatin Technologies, Inc.
There isn't enough reported data to score PTN yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
PTN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Strong |
PTN's balance sheet is currently strong, but its profitability is weak. There isn't enough data to rate its revenue and cash flow.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
PTN PE Valuation
PTN has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
PTN Forward outlook
There aren't enough analyst estimates for PTN to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
PTN Earnings Per Share
PTN and NVO do not have enough comparable growth data to identify a winner.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over PTN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over PTN on profitability, with a higher operating margin.
PTN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2024 | $350K | -80% |
| Q4 2023 | $2M | +98% |
| Q2 2023 | $1.8M | +129% |
| Q1 2023 | $1.2M | +453% |
| Q4 2022 | $1M | +311% |
| Q2 2022 | $770.7K | +340% |
| Q1 2022 | $216.1K | +144% |
PTN's revenue is growing: $300,770 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1469% | N/A |
| Q1 2026 | -40% | N/A |
| Q4 2025 | -6316% | N/A |
| Q3 2025 | 53% | N/A |
| Q2 2024 | -2383% | -1770 points |
| Q4 2023 | 58% | +602 points |
| Q3 2023 | -290% | N/A |
| Q2 2023 | -614% | +1086 points |
PTN's operating margin was −1469% last quarter, up 914 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the stronger cash trend. Its trailing FCF is down 14% versus its history, compared with PTN at down 23%.
PTN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.7M | +$1.4M |
| Q1 2026 | -$4.5M | +$898.7K |
| Q3 2025 | -$1.6M | +$5.4M |
| Q2 2025 | -$4.1M | +$2.4M |
| Q1 2025 | -$5.4M | +$3.3M |
| Q4 2023 | -$10.5M | +$6.9M |
| Q4 2022 | -$17.4M | -$11M |
| Q3 2022 | -$24.7K | +$6.5M |
PTN has burned cash in almost every quarter: −$13M over the past year, against −$27M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over PTN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
PTN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +54% | +1.4M shares |
| 1 year | +848% | +3.5M shares |
| 3 years | +1789% | +3.7M shares |
| 5 years | +1978% | +3.7M shares |
| Available history | +2262% | +3.7M shares |
PTN has 4M diluted shares, up 848% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
PTN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2020 | -2.5x | Net Cash |
| Q4 2019 | -2.5x | Net Cash |
| Q3 2019 | -2.6x | Net Cash |
| Q2 2019 | -1.2x | Net Cash |
PTN has more cash than debt.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
PTN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.7 | Neutral |
| Stochastic | 15.1 | Oversold |
PTN's weekly RSI is 38 (neutral) and its Stochastic is 15 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
PTN PE vs Healthcare Sector
PTN has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over PTN on trend strength, trading above more of its moving averages.
PTN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.12 | 7.7% below |
| 20 week MA | $8.79 | 25% below |
| 50 week MA | $14.4 | 54% below |
| 100 week MA | $17.7 | 63% below |
| 200 week MA | $63.0 | 90% below |
PTN is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over PTN on returns for 2026, with the stronger performance.
PTN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1,000.0 | $837.5 | -16% |
| 2021 | $837.5 | $650.0 | -22% |
| 2022 | $650.0 | $118.0 | -82% |
| 2023 | $118.0 | $199.0 | +69% |
| 2024 | $199.0 | $55.5 | -72% |
| 2025 | $55.5 | $14.6 | -74% |
| 2026 YTD | $14.6 | $6.57 | -55% |
PTN has finished lower in five of the last six years. It's down 55% so far in 2026.